Please login to the form below

Not currently logged in

Biogen shares peer-reviewed publication of Aduhelm phase 3 data

The trial data was published in The Journal of Prevention of Alzheimer’s Disease


Biogen has announced that a peer-reviewed manuscript has been published in The Journal of Prevention of Alzheimer’s Disease on data from the pivotal phase 3 EMERGE and ENGAGE trials for Aduhelm (aducanumab-avwa) for use in the treatment of early Alzheimer’s disease.

The article includes results from the primary, secondary and tertiary endpoints of the trials, alongside safety data and biomarker sub-studies.

The US Food and Drug Administration (FDA) granted Biogen accelerated approval for Aduhelm in June 2021 as the first Alzheimer’s disease treatment to address a defining pathology of the condition.

Aduhelm is indicated for the treatment of Alzheimer’s disease for patients with mild cognitive impairment or mild dementia – the population in which treatment was initiated in clinical trials.

A defining feature of Alzheimer’s disease is the accumulation of amyloid beta plaques in the brain. The accelerated approval of Aduhelm was based on clinical trial data that detailed the ability of Aduhelm, a monoclonal antibody, to reduce amyloid beta plaques.

There is no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.

Samantha Budd Haeberlein, senior vice president, Head of Neurodegeneration Development at Biogen, said: “We will continue to provide physicians with efficacy and safety data to help them make the best treatment decisions for patients as we learn from our ongoing trials and real-world evidence.”

Speaking on behalf of the Alzheimer Therapeutic Research Institute, University of Southern California, San Diego, Dr Paul Aisen said: “The peer reviewed publication of this data is a testament to the importance of the findings for the scientific and Alzheimer’s disease communities.”

He added: “Alzheimer’s disease is an incredibly complex condition, and this dataset is critical to advancing the understanding of the phase 3 results.”

Article by
Fleur Jeffries

17th March 2022

From: Research



Subscribe to our email news alerts

Featured jobs


Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation